Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Funnycomb777 please tell us on why we should buy warrants
So the newbies win by selling at their cost average of 25 cents and have to pay short term capital gains of 40%. That’s how they win!?!?!!?????? LMAO. U HAVE BETTER LUCK SELLING THEM WARRANTS at least that would just be money they loss not a massive tax hit.
Remember every newbie (within last 16 months) here has a cost average below $1
Neither did McNally. Titan stills owns IP and Medtronic licensed 16-20 of Titans over 170 patents.
Weeeeellllllll…….. we’re waiting!
U didn’t build a single port robotic system and you didn’t negotiate a partnership with Medtronic that McNally did. You tried pushing useless warrants w no chance to be in the money.
$1.18 - weeeeeellllllll……. We’re waiting!
$1.18 - Weeeeeellllllll……. We’re waiting!
Some facts to consider, Medtronic is licensing tech and IP (they did not buy the IP and do not own it). Any IP developed during this agreement is CO-OWNED by Titan and Medtronic. There is no way that Medtronic will walk away and allow another entity to come in and acquire Titan and all their IP and then hold that over Medtronic's head. There is no way Medtronic will allow another entity to have control of IP that is being utilized in their platform and allow that entity to employ that tech and IP in their own system. Completely Illogical. Also, the acquirer of Titan can rip up any old agreement and then completely screw Medtronic - again, completely ILLOGICAL.
As for the argument that it doesn't matter they already have it in their system so they don't need Titan, doesn't hold water b/c if they want to compete in the space, they can't let any other big Medtech (esp JNJ or ISRG) to acquire all the IP of Titan and just integrate the game changing IP into their own system which would then render Medtronic's IP and system advantages useless b/c they would have the same IP and advantages. I will say this, if Geoff Martha ends up letting Titan walk and it is scooped up by another major competitor in that space or worse let the 800 lb gorilla ISRG buy it, it might very well cost him his job. CEO's that make a blunder like that will not last long and Murtha seems to be a guy who is buttoned up and thinking long term. Remember that Murtha says that the future of Medtronic and their #1 priority is Surgical Robotics.
There is a reason ISRG is as dominant as they have been is b/c they have IP and no one was able to crack thru it until the IP started expiring. Imagine if ISRG didn't lock down their IP, they would not have become the giant in surgical robotics that they have become. All that points to the importance of anyone getting into this space to lock down IP - Medtronic will/should do the same.
So in order to compete with ISRG any competitor will need Multi-port, single-port and endoluminal. So let's take a look at Medtronic - we know that their Multi Port will be Hugo and their (IMO) Single Port will be Titan, where will the endoluminal platform come from? Will it be based off their 4 year secret agreement with Karl Storz?
https://www.fiercebiotech.com/medtech/medtronic-reveals-past-karl-storz-team-up-ahead-robotic-surgery-unveiling
Will it be another endoluminal player that will also be acquired by Medtronic?
Is Milestone 4 the delivery of an endoluminal platform for Medtronic? Is Milestone 4 delivery of snake arm technology with end effectors incorporating wrist roll technology for an endoluminal platform?
This is a long game for Medtronic, they understand the importance of Robotic Surgery for the next 20+ years. So in the short term, will HUGO alone be enough for them to compete with ISRG over the next 5 years, will Hugo alone be enough for them to hold off increased competition, which is happening.
They also have to be thinking about IP and how incredibly important it is in this space to protecting this business. It would be incredibly important to also have an R&D arm that is innovating in this space rapidly and developing patent and IP. Not only would it allow protection of the early revenue but also provide a great avenue for future growth in the next frontier of Robotic Surgery 7-10 years from now.
So when I look at Titan and they have a SINGLE PORT PLATFORM coming up on regulatory submission. They have IP (over 170) that protects their SINGLE PORT PLATFORM but can ALSO ENHANCE OTHER PLATFORMS (i.e. Hugo). The IP also provides the basis for future innovation in Robotic Surgery. Titan is also cranking out patents at a rapid pace thru their R&D.
If I took out Medtronic and Titan and laid out the above scenario with company A and Company B - almost everyone would look at that and say the value of company B to company A is worth Billions. The revenue projections alone in robotic surgery are growing exponentially year after year. ISRG is over a $100B MC on $4B in sales. Medtronic's FY19 revenue was $30.5B, their current MC is $165B - imagine what $4B in robotic surgery revenue would mean to Medtronic MC - what about $10B in revenue? $20B? You could do the same exercise for JNJ or Olympus or any medical device player looking at Robotic Surgery.
We've seen CMR valued at $3B - Vicarious is valued at $1.1B - do they bring as much value to a big medical player like company B does? I don't think so.
$1.18- Weeeeeeellllllll..........we're waiting!
$1.69
How about that $1.18 prediction, only one thing to say - WWeeeeeellllllll......we're waiting!
I'll take it real slow here so all can understand, we are closer to $1.70 then $1.18. Shorters are a bunch of helens, oh vey.....
$1.18 - WWeeeeeeeeelllllll........we're waiting!
I'm guessing that last week was the last gasp by shorters. seems like a huge loss at $1.70 when short position was $1.18. once the push for warrants started coming out, you could sense the desperation.
Titan delivers 2 new patents today alone - let's see in one day they have delivered half as many patents as Vicarious has done in 10 years. Clear to me that Vicarious has very, very little to offer to any company A and they are valued at $1.1B.
$1.18 - Weeeeellllllll.......we're waiting!
I DO NOT think another licensing agreement is coming. IMO, it will be a regulatory and commercial agreement with equity stake
So in order to compete with ISRG any competitor will need Multi-port, single-port and endoluminal. So let's take a look at Medtronic - we know that their Multi Port will be Hugo and their (IMO) Single Port will be Titan, where will the endoluminal platform come from? Will it be based off their 4 year secret agreement with Karl Storz?
https://www.fiercebiotech.com/medtech/medtronic-reveals-past-karl-storz-team-up-ahead-robotic-surgery-unveiling
Will it be another endoluminal player that will also be acquired by Medtronic?
Is Milestone 4 the delivery of an endoluminal platform for Medtronic? Is Milestone 4 delivery of snake arm technology with end effectors incorporating wrist roll technology for an endoluminal platform?
This is a long game for Medtronic, they understand the importance of Robotic Surgery for the next 20+ years. So in the short term, will HUGO alone be enough for them to compete with ISRG over the next 5 years, will Hugo alone be enough for them to hold off increased competition, which is happening.
They also have to be thinking about IP and how incredibly important it is in this space to protecting this business. It would be incredibly important to also have an R&D arm that is innovating in this space rapidly and developing patent and IP. Not only would it allow protection of the early revenue but also provide a great avenue for future growth in the next frontier of Robotic Surgery 7-10 years from now.
So when I look at Titan and they have a SINGLE PORT PLATFORM coming up on regulatory submission. They have IP (over 170) that protects their SINGLE PORT PLATFORM but can ALSO ENHANCE OTHER PLATFORMS (i.e. Hugo). The IP also provides the basis for future innovation in Robotic Surgery. Titan is also cranking out patents at a rapid pace thru their R&D.
If I took out Medtronic and Titan and laid out the above scenario with company A and Company B - almost everyone would look at that and say the value of company B to company A is worth Billions. The revenue projections alone in robotic surgery are growing exponentially year after year. ISRG is over a $100B MC on $4B in sales. Medtronic's FY19 revenue was $30.5B, their current MC is $165B - imagine what $4B in robotic surgery revenue would mean to Medtronic MC - what about $10B in revenue? $20B? You could do the same exercise for JNJ or Olympus or any medical device player looking at Robotic Surgery.
We've seen CMR valued at $3B - Vicarious is valued at $1.1B - do they bring as much value to a big medical player like company B does? I don't think so.
Someone was announcing PPS by the minute but has seemed to disappear - last pps update they gave was $1.51 - it's $1.64 today!! LMAO.
$1.18 - Weeeeeeellllllll........we're waiting
$1.18 - Weeeeeeelllllll.......we're waiting!!
Blood bath in the market today and Titan is up. Its up in after hours to $1.64 - getting further away from $1.18 on a day that was a GIFT to shorters - should have taken this down to $1.40, oh vey...bunch of helens.
He doesn’t know.
Better start backtracking on IREP used in ENOS. And start backtracking on your “I’m a shareholder” since we all know u sold out at 25 cents. Apparently a lot u will have to backtrack on.
But you are EXPECTING REGULATORY SUBMITTAL (per your own post) after milestone 4.
Would like to see those who are pushing the warrants explain this one - looks like its a bad investment to buy TTLLF
So I know that Titan is not going it alone, if they were I’d sell all my shares as I have said before. But I haven’t sold shares so they are not going it alone.
Per Canadian Regulatory - Currently, the TMD.WT.I (TTLLF) warrants are exercisable at 75 cents per share until 5 p.m. Toronto time on Sept. 20, 2021. As a result of the rollback, 30 such warrants will be exercisable into one postcosolidated share of the company, on or after June 19, 2018, at $22.50 per share, until 5 p.m. Toronto time on Sept. 20, 2021.
Some facts to consider, Medtronic is licensing tech and IP (they did not buy the IP and do not own it). Any IP developed during this agreement is CO-OWNED by Titan and Medtronic. There is no way that Medtronic will walk away and allow another entity to come in and acquire Titan and all their IP and then hold that over Medtronic's head. There is no way Medtronic will allow another entity to have control of IP that is being utilized in their platform and allow that entity to employ that tech and IP in their own system. Completely Illogical. Also, the acquirer of Titan can rip up any old agreement and then completely screw Medtronic - again, completely ILLOGICAL.
As for the argument that it doesn't matter they already have it in their system so they don't need Titan, doesn't hold water b/c if they want to compete in the space, they can't let any other big Medtech (esp JNJ or ISRG) to acquire all the IP of Titan and just integrate the game changing IP into their own system which would then render Medtronic's IP and system advantages useless b/c they would have the same IP and advantages. I will say this, if Geoff Martha ends up letting Titan walk and it is scooped up by another major competitor in that space or worse let the 800 lb gorilla ISRG buy it, it might very well cost him his job. CEO's that make a blunder like that will not last long and Murtha seems to be a guy who is buttoned up and thinking long term. Remember that Murtha says that the future of Medtronic and their #1 priority is Surgical Robotics.
There is a reason ISRG is as dominant as they have been is b/c they have IP and no one was able to crack thru it until the IP started expiring. Imagine if ISRG didn't lock down their IP, they would not have become the giant in surgical robotics that they have become. All that points to the importance of anyone getting into this space to lock down IP - Medtronic will/should do the same.
Titan is developing an endoluminal prototype w Titan IP in it.
Reminder for anyone not paying attention: in order for anyone to compete w ISRG they will need multi port, single port and endoluminal. So what does Medtronic have, they have a multi port system called Hugo, they will need an endoluminal system (we will call this milestone 4 prototype) and they will need a single port system (Enos)
Auris (endoluminal - one indication) went for $5.7B. The software science project vicarious w NO PATENT PROTECTION is a POS knock off single port system valued at $1.1B (btw it’s single indication is hernias). ISRG SP - single indication - has added over $8B in MC to ISRG.
IT is very easy to get to a multi billion dollar valuation w Titan considering they will deliver an endoluminal prototype w Titan IP, they have a next generation surgical robotic single port system, their IP will enhance second generation HUGO SYSTEM, they have a world class R&D team and one of the best IP portfolios in the surgical robotic space.
Lot of longs are just sitting back and waiting and then will be buying at $X.XX. My money tree will be in full bloom very soon and it’s an OAK of a tree. Obviously no need to buy right now as this is being taken down so it’s pretty easy just sitting here and watching. Nothing matters right now, certainly not PPS bc Titan will hit milestone 4, get tens of millions of dollars, will have a unparalleled single port system, 200 patents by then and a world class R&D TEAM.
I'm in the $4-6B camp so I feel that I can answer. IMO, I believe that upon completion of Milestone 4, Medtronic and Titan will enter into another agreement around Regulatory submittal and Commercialization, involving equity stake in Q4 2021 - Q1 2022.
Milestone 4 is due at the end of Sept. So when Milestone 4 is hit and Titan announces it and receives payment what are the next options.
Option 1. Titan receives money, pays off loan and has a Single Port Surgical robotic platform ready for Regulatory Submittal. They decide to go it alone.
Option 2. Medtronic buys out Titan immediately for one lump sum of money (its pretty clear that the BO range projections on this board have an extremely wide spread)
Option 3. Titan and Medtronic enter into another agreement (similar to Mazor deal) where Medtronic takes an equity stake and helps Titan thru human clinical trials, regulatory process and commercialization process.
Option 4. Another player comes in and makes an extremely attractive offer to buy ENOS, Entire Intellectual property portfolio and the world class R&D team.
Option 5. Titan decides to license IP and know how (consistent revenue stream)to other companies eager to get into Surgical robotic space, continues to crank out patents and still has a Single Port Surgical Robotic platform.
When prototype is delivered, I lean towards Option 3, it makes the most sense from both parties and the most logical. It will allow Medtronic to make the ultimate commitment to surgical robotics and Titan and deliver surgical robotic platforms that will be an alternative to ISRG and quite frankly a better platform. Also, acquiring the Single Port platform prevents another company from coming in and acquiring it(some argue the Medtronic can just develop a single port in house but Titan would be a prime competitor with no patent infringement - quite attractive to a JNJ, ISRG, CMR, Stryker, Olympus, etc).
Option 3 would allow Medtronic to collect all the clinical data and studies from ENOS to help in their upstream and downstream marketing. It would also allow them to get in early to help set up manufacturing, supply chain and logistics so when roll out happens its seamless (unlike the Mazor acquistion).
Option 3 would help them tremendously with the HUGO rollout b/c as they speak to CEOs and CIOs of health system, its quite an attractive package to talk about multi-port, single port and endoluminal ALONG with all of Medtronic's other business with their system/facilities.
Option 3 would allow them to move with speed thru the clinical and regulatory process b/c they would be sponsoring Titan and allow Titan to run point with assistance from Medtronic (especially b/c Medtronic will be coming off the heels of their own clinical trials across facilities where the road has been paved). Hospitals and clinicians would be familiar with the shared IP in the systems (i.e hand pieces, ergonomic physician station, etc)
I am hoping for Option 3 b/c I believe as a shareholder that is the best option for my return on investment. Options 1, 2, 4 and 5 all will lead to appreciation but maybe not at the rate of return Option 3 would.
It will be fascinating to say the least and I know every single person who comes on this board is wondering what Option will it be.
No one on this board expects the pps to hit the $16 strike price before milestone 4. I certainly don’t and therefore the warrants would expire worthless. If anyone wants to know how that worked out, there was a poster cptsjd who sold all his shares to hedge his position and bought all warrants. All those warrants expired worthless and he lost it all, LOST IT ALL!
It’s a cautionary tale of what will happen when u sell ur shares to buy warrants that expire worthless.
Anyone who wants to buy the TTLLF warrants- wait until Oct 1. That is the best move u can make.
Funny bc Marty bernholtz holds 100,000 TTLLF warrants and that is exactly how many honeycomb1.18 is trying to sell for him. I wouldn’t touch those warrants until October 1, then I’ll buy.
My cost average is 25 cents.
The rise of single port has begun. More and more procedures being done and now taking procedures that were done w multi port requiring hospital stays to being done in outpatient environment
https://consultqd.clevelandclinic.org/first-of-its-kind-approach-transvesical-radical-prostatectomy-using-the-single-port-robot-system/
Please sticky post 129808
Before McNally got here and cleaned up the mess left behind, this guys accumulated a ton of warrants and now trying to unload them.
https://www.osc.ca/en/tribunal/tribunal-proceedings/bernholtz-re/statement-allegations-matter-martin-bernholtz
He is asking for his buddy Marty bernholtz who is trying to unload his TTLLF warrants.
Someone is better off taking the $1400 and buying 850 shares of Titan bc in October when it is trading at $4, that $1400 will worth $4250 - not a bad return for 2 months. If u take that $1400 and buy warrants, 100% they expire worthless and u lost that $1400, when if u just bought shares you’d make 3x return in 2 months.
Bernholtz is trying to unload TTLLF warrants - I wouldn’t buy bc I might get ensnarled in some of his illegal activity
http://www.westlawecarswell.com/oscb/on4229/4229-final.pdf
Check out pages 39-44
I can only think of one reason someone is pushing warrants on others so their partner bernholtz can unload them. I was told that the guy pushing people to buy warrants won’t buy them himself. I figured it out, honeycomb777 is David bernholtz- Marty bernholtz son, hence the big push to try to get people to take warrants off their hands.
#shady
#beware and be aware
U can tell bernholtz that I wouldn’t touch the warrants he is unloading and u r pushing for him. Sure, u get this to $1.18 and I will say that congrats u got it there so….
$1.18- Weeeeeelllllllll…….. we’re waiting!
Remember that IREP19 is EXPECTING REGULATORY SUBMITTAL after Milestone 4 - reminder that was HIS POST!